Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
JP Morgan Maintains Underweight on AnaptysBio, Raises Price Target to $32
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Underweight and raises the price target from $24 to $32.
Expert Ratings for AnaptysBio
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Guggenheim Upgrades AnaptysBio to Buy
Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.
AnaptysBio And GSK-Partnered Immuno-Oncology Agents JEMPERLI (dostarlimab-gxly) And Cobolimab Show Progress In Two Separate Non-small Cell Lung Cancer Trials
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
Positive headline results from PERLA, a head-to
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
HC Wainwright is assuming coverage on AnaptysBio Inc (NASDAQ:ANAB) with a Buy Rating and a price target of $35 at a unique inflection…
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $35
HC Wainwright & Co. analyst Gobind Singh assumes AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $35.
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday.
Benzinga’s Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades
See all analyst ratings upgrades.
Truist Securities Downgrades AnaptysBio to Hold, Lowers Price Target to $28
Truist Securities analyst John Lee downgrades AnaptysBio (NASDAQ:ANAB) from Buy to Hold and lowers the price target from $50 to $28.